Guidelines for antiretroviral therapy in adults
Guidelines for antiretroviral therapy in adults
复制标题
DOI：
10.7196/sajhivmed.862
复制
发表时间：
2012-09-01
影响因子：
1.7
通讯作者：
Spencer, Dave
中科院分区：
文献类型：
--
作者：
Meintjes, Graeme;Maartens, Gary;Spencer, Dave
这些指南旨在更新2008年1月在《南部非洲艾滋病毒医学杂志》上发表的指南。自上一份准则发布以来，南部非洲抗逆转录病毒疗法的规模继续扩大。该地区的队列研究显示了良好的临床结果;然而，抗逆转录病毒疗法仍然起步较晚（在晚期疾病中），导致早期死亡率相对较高。现已获得关于该区域抗逆转录病毒药物耐受性的新数据和几种新的抗逆转录病毒药物。虽然目前数量很少，但该地区的一些患者正在失败的蛋白酶抑制剂（PI）为基础的二线方案。为了解决这个问题，三线（或“挽救”）治疗的指导方针已经扩大。
These guidelines are intended as an update to those published in the Southern African Journal of HIV Medicine in January 2008. Since the release of the previous guidelines, the scale-up of antiretroviral therapy (ART) in Southern Africa has continued to grow. Cohort studies from the region show excellent clinical outcomes; however, ART is still being started late (in advanced disease), resulting in relatively high early mortality rates. New data on antiretroviral (ARV) tolerability in the region and several new ARV drugs have become available. Although currently few in number, some patients in the region are failing protease inhibitor (PI)-based second-line regimens. To address this, guidelines on third-line (or 'salvage') therapy have been expanded.